PDE4 inhibitors 1998

Bibliography

• ALDOUS D, KARLSSON JA: Phosphodiesterase 4 inhibi- tors for the treatment of asthma. Exp. Opin. Ther. Patents (1997) 7(9):989–1003.
   Web of Science ®Google Scholar
• •Comprehensive review of scientific and patent literature to early 1997
   Google Scholar
• TORPHY TJ: Phosphodiesterase isozymes. molecular targets for novel antiasthma agents. Am. J. Respir. Grit. Care Med. (1998) 157:351–370.
   Google Scholar
• ••Excellent review by one of the leaders in this field.
   Google Scholar
• New drugs in the R&D pipeline Pharma Jpn. (1997) 1565:19–23.
   Google Scholar
• BOBON D, BREULET M, GERARD-VANDENHOVE MA et al. Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur. Arch. Psychiat. Neurol. Sci. (1988) 238:2–6.
   PubMedGoogle Scholar
• LAS-31025. Clin. Trials Monitor (1997) 69:25–26.
   Google Scholar
• GRISTWOOD R: Third International Conference on Cyclic Nucleotide Phosphodiesterases: From Genes to Therapies. Glasgow (1996).
   Google Scholar
• BARNETTE MS, CHRISTENSEN SB, ESSAYAN DM et al.: SB207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. J. Pharmacol Exp. Ther. (1998) 284:420–426.
   PubMed Web of Science ®Google Scholar
• SmithKline Beecham R&D Review Meeting. London,16th April 1998.
   Google Scholar
• CHRISTENSEN SB, GUIDER AM, FORSTER CJ et al.: 1,4-Cyclohexane carboxylates: potent and selective in-hibitors of phosphodiesterase 4 for the treatment of asthma. J. Merl. Chem. (1998) 41:821–835.
   PubMed Web of Science ®Google Scholar
• •Highlights the selection criteria used to try and minimise po-tential side-effects.
   Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S, HAYDWP, TORPHY TJ: The therapeutic activity of SB 207499 (Ariflo), a second generation phosphodiesterase 4 (PDE4) inhibitor, is equivalent to that of prednisolone in models of pulmonary inflammation. Am. J. Respir. Grit. Care Med. (1998) 157:Poster B60.
   Google Scholar
• MURDOCH RD, COWLEY H, UPWARD J, WEBBER D, WYLD P: The safety and tolerability of Ariflo (SB 207499), a novel and selective phosphodiesterase 4 in-hibitor, in healthy male volunteers. Am. J. Respir. Grit. Care Med. (1998) 157:Poster L57.
   Google Scholar
• NIEMAN RB, FISHER BD, AMIT 0, DOCKHORN RJ: SB 207499 (ARIFLO), a second-generation, selective oral phosphodiesterase type 4 (PDE4) inhibitor, attenuates exercise induced bronchoconstriction in patients with asthma. Am. J. Respir. Grit. Care Med. (1998) 157:Poster L81.
   Google Scholar
• HANIFIN JM, CHAN SC, CHENG JB, TOFTE SR, HENDER-SON WR: Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J. Invest. Dermatol. (1996) 107:51–56.
   PubMed Web of Science ®Google Scholar
• •Suggesting PDE4 inhibitors may have therapeutic potential in dermatology.
   Google Scholar
• COHAN VL, SHOWELL HJ, FISHER DA et al.: In vitro phar-macology of the novel phosphodiesterase type 4 in-hibitor, CP-80633. J. Pharmacol. Exp. Ther. (1996) 278:1356–1361.
   PubMed Web of Science ®Google Scholar
• CHENG JB, WATSON JW, PAZOLES CJ et al.: The phos-phodiesterase type 4 (PDE4) inhibitor CP-80,633 ele-vates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy. J. Pharmacol Exp. Ther. (1997) 280:621–626.
   PubMed Web of Science ®Google Scholar
• CAVALLA D, GALE D: A case history of succesful virtualresearch. Drug News Perspect. (1997) 10:470–476.
   Google Scholar
• MONTANA JG: 8th Symposium on Medicinal Chemistry. Hatfield, UK (1997).
   Google Scholar
• ESCOTT KJ, MCMILLAN SJ, BIRRELL M et al.: Pharma-cological profiling of phosphodiesterase 4 (PDE4) in-hibitors and analysis of the therapeutic ratio in rats and dogs. Br. J. Pharmacol. (1998) 123:Proc. Suppl. 40.
   Google Scholar
• JONKER GJ, TIJHUIS GJ, DE MONCHY JGR: RP 73401 (A phosphodiesterase IV inhibitor) single does not pre-vent allergen induced broncho-constriction during the early phase reaction in asthmatics. Eur. Respir. J. Suppl. (1996) 9(23):82S.
   Google Scholar
• •The (surprising) lack of efficacy of the most potent PDE4 inhibitor.
   Google Scholar
• Eur. Respir. J. Suppl. (1996) 9(23):82S.
   Google Scholar
• CHIKANZA IC, JAWED SJ, BLAKE DR et al.: Treatment ofpatients with rheumatoid arthritis with RP73401 phos-phodiesterase type IV inhibitor. Arthritis Rheum. (1996) 39:9. Suppl. S282.
   Google Scholar
• SZELENYI SK, POPPE H, DENT G, MAGNUSSEN H, RABE KF: Effects of selective PDE4 inhibitor, D22888, on hu-man airways and eosinophils in vitro and late phase allergic eosinophilia in guinea pigs. Am. J. Respir. Crit. Care Med. (1997) 156:A624.
   PubMedGoogle Scholar
• MARX D, ROLLING H, SZELENYI I: Inhibition of allergen induced bronchial hyperactivity (BHR) in BP-2 mice by cyclosporine A, fluticasone and selective PDE4-inhibitors. J. Allergy Clin. Immunol. (1998) 101:S10.
   Web of Science ®Google Scholar
• TAKAYAMA K, IWATA M, OKAMOTO Y, AOKI M, NIWA A, ISOMURA Y: Synthetic studies on selective type IV phosphodiesterase (PDE IV) inhibitors. 214th ACS. Las Vegas (1997). MEDI 245.
   Google Scholar
• SHIRE MG, MULLER GW: TNF-alpha inhibitors and rheu-matoid arthritis. Exp. Opin. Ther. Patents (1998) 8:531–544.
   Web of Science ®Google Scholar
• HARBINSON PL, MACLEOD D, HAWKSWORTH R et al:The effect of a novel orally active selective PDE4 isoen-zyme inhibitor (CDP840) on allergen-induced re-sponses in asthmatic subjects. Eur. Respir. J. (1997) 10:1008–1014.
   PubMed Web of Science ®Google Scholar
• •The most detailed asthma study reported to date.
   Google Scholar
• PASCAL Y, ANDRIANJARA R, AUCLAIR E et al. Synthesis and structure activity relationships of 4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4,]diazepino lines: Novel PDE4 inhibitors. ACS (1998) MEDI 050
   Google Scholar
• HULME C, POLI GB, HUANG FC, SOUNESS JE, DJURIC SW: Quaternary substituted PDE4 inhibitors. Part 1: The synthesis and in vitro evaluation of a novel series of oxindoles. Bioorg. Med. Chem. Lett. (1998) 8:175–178.
   Google Scholar
• HULME C, MORIARTY K, HUANG FC et al.: Quaternary substituted PDE IV inhibitors. Part 2: The synthesis and in vitro evaluation of a novel series of y-lactams. Bioorg. Med. Chem. Lett. (1998) 8:399–404.
   Google Scholar
• NORMAN P: Conquering airway inflammation in the21st century. Drug News Perspect. (1997) 10:501–506.
   Google Scholar
• DUPLANTIER AJ, BIGGERS MS, CHAMBERS RJ et al.: Bi-arylcarboxylic acids and amides: inhibition of phos-phodiesterase type IV versus rlikolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. (1996) 39:120–125.
   PubMed Web of Science ®Google Scholar
• KLEINMAN EF, CAMPBELL E, GIORDANO LA et al.: Strik-ing effect of hydroxamic acid substitution on the phos-phodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implica-tions for a new active site model of PDE4. J. Med. Chem. (1998) 41:266–270.
   PubMed Web of Science ®Google Scholar
• CHAMBERS RJ, MARFAT A, CHENG JB eta].: Biarylcarbox-amide inhibitors of phosphodiesterase IV and tumor necrosis factor-a. Bioorg. Med. Chem. Lett. (1997) 7:739–744.
   Google Scholar
• GRAUL A, LEESON P, CASTANER J: T-440. Drugs Future (1997) 22:729–732.
   Google Scholar
• IWASAKI T, KONDO K, KURODA T et al.: J. Med. Chem. (1996) 39:2696–704.
   Google Scholar
• YAMAGATA S, WADA K, SUGAYA T et al.: Bronchial anti-spasmogenic effects and selectivity of T-440, phos-phodiesterase type 4 inhibitor, in the dog. Biol. Pharm. Bull. (1997) 20(12):1261–1265.
   PubMed Web of Science ®Google Scholar
• FUJII K, KOHROGI H, IWAGOE H et al.: Novel phos-phodiesterase 4 inhibitor T-440 reverses and prevents human bronchial contraction induced by allergen. J. Pharmacol. Exp. Ther. (1998) 284 (1) :162–169.
   PubMed Web of Science ®Google Scholar
• HISAMICHI H, TAKAYAMA K, IWATA M et al.: Synthesis studies on selective type IV phosphodiesterase (PDE IV) inhibitors II. ACS (1998). MEDI 049.
   Google Scholar
• SEGARRA V, CRESPO MI, PUJOL F et al.: Phosphodies-terase inhibitory properties of losartan. Design and synthesis of new lead compounds. Bioorg. Med. Chem. Lett. (1998) 8:505–510.
   PubMed Web of Science ®Google Scholar
• MULLER T, ENGELS P, FOZARD JR: Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol. ScL (1996) 17:294–298.
   PubMed Web of Science ®Google Scholar
• ENGELS P, SULLIVAN M, MULLER T, LUBBERT H: Molecu-lar cloning and functional expression in yeast of a hu-man cAMP-specific phosphodiesterase subtype (PDE IV-C). FEBS Lett. (1995) 358:305–310.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN SB et al. : Molecular aspects of inhibitor interaction with PDE4. In: Phosphodiesterase Inhibitors. Schudt, Dent, Rabe (Eds.), Academic Press, San Diego, CA (1996):41–56.
   Google Scholar
• JACOBITZ S, RYAN MD, MCLAUGHLIN MM, LIVI GP, DE-WOLF WE Jr., TORPHY TJ: Role of conserved histidines in catalytic activity and inhibitor binding of human re-combinant phosphodiesterase 4A. Mol. Pharmacol. (1997) 51:999–1006.
   Google Scholar
• JACOBITZ S, MCLAUGHLIN MM, LIVI GP, BURMAN M, TORPHY TJ: Mapping the functional domains of hu-man recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram bind-ing. Mol. Pharmacol (1996) 50:891–899.
   PubMed Web of Science ®Google Scholar
• SETTE C, CONTI M: Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase: involvement of serine 54 in the enzyme activation. J. Biol. Chem. (1996) 271:16526–16534.
   PubMed Web of Science ®Google Scholar